Re-evaluating Antibiotic Therapy Duration for Infective Endocarditis: The POET-II Trial

Q: What are the key findings of this study?

Tailored antibiotic therapy increased days alive off antibiotics (183 vs 169; p<0.001 for superiority) and was noninferior for safety (8% vs 11%; p<0.001 for noninferiority) in left-sided IE.

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Left-sided infective endocarditis (native or prosthetic valve) (n=508). Intervention: Response-tailored antibiotic therapy (immediate discontinuation upon stabilization) vs. Standard-duration antibiotic therapy (total duration of 4-6 weeks). Primary outcome: Number of days alive without antibiotic treatment for infective endocarditis or bacteraemia within 6 months (primary efficacy endpoint) (MD 13 days, 95% CI 12–13, p=<0.001 for superiority).

Q: What question did this study set out to answer?

To evaluate whether response-tailored, reduced-duration antibiotic therapy is noninferior in safety and superior in antibiotic-free days compared to standard-duration therapy for stabilized left-sided infective endocarditis.

Harish Ramakrishna; Shashank Shekhar; Seshasayee Narasimhan

doi:10.33590/emjcardiol/1u8bd088

October 8, 2026EMJ CardiologyOpen Access

Re-evaluating Antibiotic Therapy Duration for Infective Endocarditis: The POET-II Trial

View Full Paper

Ask AI

Bookmark

Share

Key result

Tailored antibiotic therapy gains ~14 days alive off antibiotics in left-sided IE without compromising safety.

MD +13 days
95% CI 12–13
P<0.001 for superiority
n=508

Key Points

To evaluate whether response-tailored, reduced-duration antibiotic therapy is noninferior in safety and superior in antibiotic-free days compared to standard-duration therapy for stabilized left-sided infective endocarditis.
Study conducted across 13 centers in Denmark, Sweden, and the USA involving 508 adults with left-sided infective endocarditis caused by S. aureus, E. faecalis, or Streptococcus species who met POET stabilization criteria after 2–4 weeks of antibiotic therapy.
Patients were randomized 1:1 to either tailored therapy with immediate antibiotic discontinuation (n=255) or standard therapy continued for a total duration of 4–6 weeks (n=253).
Tailored therapy was superior for the primary efficacy endpoint of days alive without antibiotic treatment within 6 months (183 vs 169 days; Hodges-Lehmann difference: 13 days, 95% CI: 12–13 days; p<0.001).
The primary safety composite endpoint occurred in 8% (21/255) in the tailored-therapy group versus 11% (27/253) in the standard-therapy group (95% CI: –7.7–2.7; p<0.001 for noninferiority, prespecified margin 7.5 percentage points).
Relapse of bacteremia or infective endocarditis with the primary pathogen was reported in 3% of the tailored-therapy group versus 5% of the standard-therapy group (p=0.004).

Study Design

Type

RCT (n=508)

Blinding

Open-label

Randomization

1:1 randomization

Multicenter

Yes

PICO

P

Population

508 clinically stabilized adults (mean age 70 years, ~25% female, 26% prosthetic-valve) with left-sided infective endocarditis caused by Streptococcus species, S. aureus, or E. faecalis after at least 2-4 weeks of antibiotic therapy, excluding recent relapse or immunodeficiency, followed for 6 months.

I

Intervention / Comparator

Response-tailored antibiotic therapy (immediate discontinuation upon stabilization) vs Standard-duration antibiotic therapy (total duration of 4-6 weeks)

O

Primary Outcome

Number of days alive without antibiotic treatment for infective endocarditis or bacteraemia within 6 months (primary efficacy endpoint) — MD 13 days (12–13), p=<0.001 for superiority

Main Result

Mean Difference: 13 (95% CI 12–13)

Absolute Event Rate: 183% vs 169%

p-value: p=<0.001 for superiority

Limitations

Open-label study design
Higher incidence of relapse of bacteraemia or infective endocarditis with the primary pathogen in the tailored-therapy group
Subgroup analysis showed benefits were restricted to Streptococcus or S. aureus infections, while standard therapy performed better in E. faecalis infections
Resource-intensive POET stabilization criteria require serial biochemical, imaging, and clinical assessments at experienced centres

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Reveals tailored antibiotic therapy achieves noninferior safety in left-sided infective endocarditis, indicating treatment duration can be shortened safely in select patients.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ramakrishna et al. (2026) conducted an RCT in Left-sided infective endocarditis (native or prosthetic valve) (n=508). Response-tailored antibiotic therapy (immediate discontinuation upon stabilization) vs. Standard-duration antibiotic therapy (total duration of 4-6 weeks) was evaluated on Number of days alive without antibiotic treatment for infective endocarditis or bacteraemia within 6 months (primary efficacy endpoint) (MD 13 days, 95% CI 12–13, p=<0.001 for superiority). Tailored antibiotic therapy increased days alive off antibiotics (183 vs 169; p<0.001 for superiority) and was noninferior for safety (8% vs 11%; p<0.001 for noninferiority) in left-sided IE.

synapsesocial.com/papers/6aee6c2371a7594806220de0 https://doi.org/10.33590/emjcardiol/1u8bd088

View Full Paper

Ask AI

Bookmark

Share

Re-evaluating Antibiotic Therapy Duration for Infective Endocarditis: The POET-II Trial

Key Points

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Re-evaluating Antibiotic Therapy Duration for Infective Endocarditis: The POET-II Trial

Key Points

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading